From Name

From Email

To Name

To Email

Message

ADA: AstraZeneca's Diabetes-Fighter Farxiga Cuts Risk of Fast Decline in Kidney Function

from Fierce Pharma

ADA: AstraZeneca's Diabetes-Fighter Farxiga Cuts Risk of Fast Decline in Kidney Function Fierce Pharma AstraZeneca’s Farxiga is already getting a speedy Federal Drug Administration review as a treatment for chronic kidney disease, but it’s still piling on the positive results. A new analysis of the company’s Declare-Timi 58 trial, presented at the American Diabetes Association’s virtual annual meeting, showed the drug could reduce the proportion of patients with fast-declining estimated glomerular filtration rate, a common measure of kidney function. READ MORE

more